The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging

Movement Disorders

Volumn 27, Issue 12, 2012, Pages 1484-1492

  Ray, Nicola J ^a,b,c   Strafella, Antonio P ^a,b,c  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cognition; Executive functions; FMRI; PD; PET

Indexed keywords

6 FLUORODOPA F 18; ALPHA SYNUCLEIN; DOPAMINE; FLUORODEOXYGLUCOSE F 18; RACLOPRIDE C 11;

AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; BRAIN BLOOD FLOW; CAUDATE NUCLEUS; COGNITIVE DEFECT; CORPUS STRIATUM; CORRELATION ANALYSIS; DEMENTIA; DIFFUSION TENSOR IMAGING; ELECTROENCEPHALOGRAPHY; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GLOBUS PALLIDUS; HUMAN; INFERIOR TEMPORAL CORTEX; MAGNETOENCEPHALOGRAPHY; NERVE CELL MEMBRANE POTENTIAL; NEUROBIOLOGY; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; QUALITY OF LIFE; REVIEW; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOXEL BASED MORPHOMETRY;

ANIMALS; BRAIN; COGNITION DISORDERS; HUMANS; NERVE NET; NEUROBIOLOGY; NEUROIMAGING; PARKINSON DISEASE;

EID: 84867744343     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25173     Document Type: Review

References (62)

1. Aarsland D, Kolbjørn B, Tormod F. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep 2011; 11: 371-378.
2. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Movement Disorders 2011; 26: 1814-1824.
3. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005; 18: 149-154.
4. Levy G, Jacobs MD, Tang M, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 2002; 17: 1221-1226.
5. Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 64: 178-183.
6. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins T W, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-1798.
7. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN Cohort. Brain 2009; 132: 2958-2969.
8. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-1245.
9. Cameron IGM, Pari G, Alahyane N, et al. Impaired executive function signals in motor brain regions in Parkinson's disease. NeuroImage 2012; 60: 1156-1170.
10. Alexander GE, and Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266-271.
11. Cheesman AL, Barker RA, Lewis SJG, Robbins TW, Owen AM, Brooks DJ. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1204-1210.
12. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging 2012; 33: 206.e29-39.
13. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1-23.
14. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New Engl J Med 1988; 318: 876-880.
15. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001; 11: 1136-1143.
16. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003; 41: 1431-1441.
17. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002; 125: 584-594.
18. Cools R, Lewis SJG, Clark L, Barker RA, Robbins TW. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007; 32: 180-189.
19. Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594-596.
20. Kaasinen NEN, Brück A, Eskola O, Bergman J, Solin O, Rinne JO. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 2001; 6: 1125-1130.
21. Rowe JB, Hughes L, Ghosh BCP, et al. Parkinson's disease and dopaminergic therapy-differential effects on movement, reward, and cognition. Brain 2008; 131: 2094-2105.
22. Cools R, Miyakawa A, Sheridan M, D'Esposito M. Enhanced frontal function in Parkinson's disease. Brain 2010; 133: 225-233.
23. Nakamura T, Ghilardi MF, Mentis M, et al. Functional networks in motor sequence learning: abnormal topographies in Parkinson's disease. Hum Brain Mapp 2001; 12: 42-60.
24. Feigin A, Ghilardi MF, Carbon M, et al. Effects of levodopa on motor sequence learning in Parkinson's disease. Neurology 2003; 60: 1744-1749.
25. Monchi O, Petrides M, Mejia-Constain B, Strafella AP. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007; 130: 233-244.
26. Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008; 131: 1294-1302.
27. Ko JH, Antonelli F, Monchi O, et al. Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease. Human Brain Mapping 2012 Feb 14. doi: 10.1002/hbm.22006.
28. Durstewitz D, Seamans JK. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol Psychiatry 2008; 64: 739-749.
29. Hong S, Hikosaka O. Dopamine-mediated learning and switching in cortico-striatal circuit explain behavioral changes in reinforcement learning. Front Behav Neurosci 2011; 5: 15.
30. Marklund P, Larsson A, Elgh E, et al. Temporal dynamics of basal ganglia under-recruitment in Parkinson's disease: transient caudate abnormalities during updating of working memory. Brain 2009; 132: 336-346.
31. van Beilen M, Portman AT, Kiers HAL, et al. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat Disord 2008; 14: 224-228.
32. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255-1263.
33. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54: 1916-1921.
34. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. Acta Neuropathol 2010: 120: 131-143.
35. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988; 1: 24-36.
36. Foster R, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010; 25: 2516-2523.
37. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
38. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011; 134: 1493-1505.
39. Brooks DJ. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy Bodies with positron emission tomography. Mov Disord 2009; 24: S742-S747.
40. Shin J, Kepe V, Small GW, Phelps ME, Barrio JR. Multimodal imaging of Alzheimer pathophysiology in the brain's default mode network. Int J Alzheimer's Dis 2011; 2011: 687945.
41. Lee VMY, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 2006; 52: 33-38.
42. Perry EK, Curtis M, Dick DJ. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985; 48: 413-421.
43. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-892.
44. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60: 1745-1748.
45. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253: 242-247.
46. Cropley VL, Fujita M, Bara-Jimenez W, et al. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008; 163: 171-182.
47. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 11: 1716-1722.
48. Song IU, Kim YD, Cho JH, Chung SW, Chung YA. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia. Alzheimer Dis Assoc Disord 2012 Feb 17. doi: 10.1097/WAD.0b013e31824acd84.
49. Pappatà S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naive Patients with PD is associated with cerebral hypometabolism. Neurology 2011; 77: 1357-1362.
50. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73: 273-278.
51. Bohnen NI, Müller MLTM, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012 May 19. doi: 10.1038/jcbfm.2012.60.
52. Kotagal V, Albin RL, Müller MLTM, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012; 71: 560-568.
53. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52: 848-855.
54. Yilong M, Huang C, Dyke JP, et al. Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab 2010; 30: 505-509.
55. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. NeuroImage 2007; 34: 714-723.
56. Ma Y, Tang C, Spetsieris GP, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab 2006; 27: 597-605.
57. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008; 70: 1470-1477.
58. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52: 848-855.
59. Hattori T, Orimo S, Aoki S, et al. Cognitive status correlates with white matter alteration in Parkinson's disease. Hum Brain Mapp 2012; 33: 727-739.
60. Ibarretxe-Bilbao N, Junque C, Marti MJ, Tolosa E. Brain structural MRI correlates of cognitive dysfunctions in Parkinson's disease. J Neurol Sci 2011; 310: 70-74.
61. Daniel W, Doshi J, Koka D, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011; 68: 1562-1568.
62. Kehagia AA, Roger AB, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200-1213.